Xeris Biopharma Projects Strong Revenue Growth for 2024

Xeris Biopharma's Promising Revenue Forecast for 2024

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) has recently set an ambitious revenue goal for the upcoming year, projecting total revenue for 2024 to hit $203 million. This figure significantly surpasses the previous estimate that ranged from $198 million to $202 million, showcasing Xeris's robust growth in the biopharmaceutical sector.

Remarkable Revenue Growth

The company recorded an impressive 22.7% increase in revenue over the past year, reflecting its strong operational performance and effective market strategies. Xeris is expected to close the year positively, with an exceeding cash reserve of over $71 million in cash, cash equivalents, and short-term investments. This financial stability comes on the heels of a productive fourth quarter, where Xeris generated positive cash flow, further solidifying its strong position in the market.

Recorlev® and Gvoke® Driving Performance

A key contributor to Xeris's revenue growth has been the successful uptake of its product Recorlev®, which is specifically designed to treat endogenous Cushing’s syndrome. In the fourth quarter alone, the revenue for Recorlev® is anticipated to increase by around $5 million, marking a 28% sequential rise. This surge reflects a record number of newly diagnosed patients and increased referrals during this period.

Another flagship product, Gvoke®, a ready-to-use glucagon solution for severe hypoglycemia, concluded the year with a commendable 35% market share. The consistent demand for both Recorlev and Gvoke highlights the company's ability to meet critical healthcare needs effectively.

Strategic Developments and Partnerships

Fourth quarter advancements also included a significant milestone payment of $3 million from Beta Bionics, Inc. This payment was awarded for the formulation of a unique XeriSol® glucagon formulation aimed specifically for bi-hormonal pumps, showcasing Xeris's commitment to innovation in drug delivery systems.

License Agreement Changes

Despite these successes, Xeris faced a challenge when Amgen (NASDAQ: AMGN) decided to terminate its exclusive worldwide licensing agreement with the company. Yet, it’s important to note that this decision arose from a broader reassessment of Amgen’s global portfolio and does not reflect any shortcomings in Xeris's XeriJect® formulation technology. As a result, Xeris's market outlook remains largely unaffected.

Leadership Insights and Market Position

John Shannon, the CEO of Xeris, has expressed confidence in the company’s prospective growth, attributing it to the strong demand for both Recorlev and Gvoke. He also emphasized the strength of their pipeline, particularly the Phase 3 ready XP-8121 program targeting hypothyroidism, which he believes sets an exciting foundation for a transformative 2025.

Xeris's official financial results for 2024 are set to be released in early March 2025, which will provide further insight into the company's performance and strategic direction.

Investor Outlook and Recent Analyst Activity

Xeris Pharmaceuticals (NASDAQ: XERS) has drawn significant attention due to its noteworthy financial performance. The company recently celebrated its ninth consecutive beat on revenue estimates and has revised its sales guidance for 2024 to a target of $198-202 million. Coupled with an improved year-end cash balance forecast, now expected to range between $68-72 million, Xeris has substantially reduced its operating losses, resulting in a 35% increase in net income and earnings per share.

Analyst Ratings and Market Reactions

In light of these developments, H.C. Wainwright responded by increasing its price target for Xeris Pharmaceuticals from $6.00 to $6.60 while maintaining a 'Buy' rating. Conversely, Piper Sandler adjusted its previous 'Overweight' rating to 'Neutral' because of concerns regarding the company’s cost structure.

Moreover, Recorlev's performance exceeded expectations with reported revenue of $17.7 million, 18% above market consensus. Additionally, progress is being made on the once-weekly levothyroxine autoinjector, XP-8121, which previously demonstrated promising Phase 2 data.

Frequently Asked Questions

What is Xeris Biopharma's projected revenue for 2024?

Xeris Biopharma projects a revenue of $203 million for the year 2024, exceeding previous estimates.

What are the main products contributing to Xeris's revenue?

Main products driving revenue include Recorlev® for Cushing's syndrome and Gvoke® for severe hypoglycemia.

Who is the CEO of Xeris Biopharma?

The CEO of Xeris Biopharma is John Shannon, who is optimistic about the company’s growth path.

What recent changes occurred with Amgen regarding Xeris?

Amgen terminated its licensing agreement with Xeris, but this change is not expected to impact Xeris's financial outlook.

When will Xeris release its official financial results for 2024?

Xeris’s financial results for 2024 are anticipated to be released in early March 2025.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.